0000000000341835

AUTHOR

M. Del Prete

showing 3 related works from this author

Influence of comorbidity and cognitive status on instrumental activities of daily living in amnestic mild cognitive impairment: results from the ReGA…

2007

Objectives To investigate whether amnestic mild cognitive impairment (aMCI) is characterised by restriction in instrumental activities of daily living (IADL). Further, to examine the role of comorbidity and cognitive performance on IADL changes in aMCI subjects. Methods The study included 132 subjects with aMCI and 249 subjects with no cognitive impairment (NCI), consecutively enrolled as outpatients in a multicentric Italian clinical-based study, the ReGAl Project. All subjects underwent a comprehensive evaluation including clinical examination, laboratory screening, neuroimaging and cognitive and behavioral assessments. Functional status was evaluated by the Lawton's Instrumental Activiti…

GerontologyMalemedicine.medical_specialtyActivities of daily livingSettore MED/25 - PSCHIATRIAComorbidityNeuropsychological Testsbehavioral disciplines and activitiesDisability EvaluationMental ProcessesRating scaleExecutive functionmental disordersmedicine80 and overHumansEffects of sleep deprivation on cognitive performanceCognitive performanceAgedGeriatricsCognitive evaluation theoryAged 80 and overDepressive DisorderCognitive disorderActivities of daily livingMild cognitive impairmentCognitionmedicine.diseaseComorbidityActivities of daily living; Cognitive performance; Comorbidity; Executive function; Mild cognitive impairment; Activities of Daily Living; Aged; Aged 80 and over; Amnesia; Comorbidity; Depressive Disorder; Disability Evaluation; Female; Humans; Male; Mental Processes; Neuropsychological Tests; Geriatrics and Gerontology; Psychiatry and Mental HealthPsychiatry and Mental HealthSettore MED/26 - NeurologiaFemaleactivities of the day livingAmnesiaGeriatrics and GerontologyPsychologyhuman activities
researchProduct

TH-302 + Gemcitabine (G + T) vs Gemcitabine (G) in Patients with Previously Untreated advanced Pancreatic Cancer (PAC)

2012

ABSTRACT Background TH-302 is a hypoxia targeted prodrug with a hypoxia-triggered 2-nitroimidazole component designed to release the DNA alkylator, bromo-isophosphoramide mustard (Br-IPM), when reduced in severe hypoxia. A randomized Phase 2B study (NCT01144455) was conducted to assess the benefit of G + T to standard dose G as first-line therapy of PAC. Materials and methods An open-label multi-center study of two dose levels of TH-302 (240 mg/m2 or 340 mg/m2) in combination with G versus G alone (randomized 1:1:1). G (1000 mg/m2) and T were administered IV over 30-60 minutes on Days 1, 8 and 15 of a 28-day cycle. Patients on the G could crossover after progression and be randomized to a G…

medicine.medical_specialtyGastrointestinal tumorsPerformance statusbusiness.industryHematologySevere hypoxiaNeutropeniamedicine.diseaseRashGastroenterologyDiscontinuationNon colorectalOncologyInternal medicineToxicitymedicinemedicine.symptombusinessAnnals of Oncology
researchProduct

RANDOMIZED PHASE II STUDY OF FIRST-LINE EVEROLIMUS (EVE) + BEVACIZUMAB (BEV) VERSUS INTERFERON ALFA-2A (IFN) + BEV IN PATIENTS (PTS) WITH METASTATIC …

2012

ABSTRACT Background Study results demonstrated that IFN augments BEV activity and improves median PFS in pts with mRCC. Thus, combination BEV + IFN is a standard first-line treatment option for mRCC. Combining BEV with the mTOR inhibitor EVE may be an efficacious and well-tolerated treatment option. The open-label, phase II RECORD-2 trial compared first-line EVE + BEV and IFN + BEV in mRCC. Patients and methods: Therapy-naive pts with clear cell mRCC and prior nephrectomy were randomized 1:1 to BEV 10 mg/kg IV every 2 weeks with either EVE 10 mg oral daily or IFN (9 MIU SC 3 times/week, if tolerated). Tumour assessments were every 12 weeks. Primary objective was treatment effect on progress…

medicine.medical_specialtymedicine.medical_treatmentGastroenterology03 medical and health sciences0302 clinical medicineProstateInternal medicinemedicineStomatitisObjective response030304 developmental biology0303 health sciencesProteinuriaGenitourinary systembusiness.industryTreatment optionsHematologymedicine.diseaseNephrectomy3. Good healthmedicine.anatomical_structureOncologyTolerability030220 oncology & carcinogenesismedicine.symptombusinessAnnals of Oncology
researchProduct